Novel compounds targeting InhA for TB therapy

AlMatara M., Makky E. A. , VAR I. , KAYAR B., KÖKSAL F.

PHARMACOLOGICAL REPORTS, cilt.70, ss.217-226, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 70 Konu: 2
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.pharep.2017.09.001
  • Sayfa Sayıları: ss.217-226


Tuberculosis (TB) is described as lethal disease in the world. Resistant to TB drugs is the main reason to have unfavourable outcomes in the treatment of TB. Therefore, new agents to replace existing drugs are urgently needed. Previous reports suggested that InhA inhibitors, an enoyl-ACP-reductase, might provide auspicious candidates which can be developed into novel antitubercular agents. In this review, we explain the role of InhA in the resistance of isoniazid. Furthermore, five classes of InhA inhibitors, which display novel binding modes and deliver evidence of their prosperous target engagement, have been debated. (C) 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o. o. All rights reserved.